Pleiotropic Effects of Sodium glucose co-transporter 2 inhibitor on sympathetic nerve activity and organ network in patients with Type 2 diabetes - Effect of SGLT2 inhibitor on sympathetic nerve activity and orgam network

TAKAMURA Toshinari0 个研究点目标入组 40 人开始时间: 2020年7月20日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•Main inclusion criteria
•Previous history of cardiovascular diseases, ischemic stroke, and heart failure. And/or at least one of the following conditions (Hypertension, dyslipidemia, high age(male: above 50, female: above 55), smoking history, obesity (BMI above 25)).
•Type 2 diabetes, HbA1c >=7.0%

•Main exclusion criteria
•1) luseogliflozin or glimepiride hypersensitivity or contraindications, 2) treatment with glinide, sulfonylurea, and SGLT2 inhibitor including luseogliflozin within 4 weeks of screening, 3) type 1 diabetes or gestational diabetes, 4) diabetic ketoacidosis, hyperosmolar hyperglycemic state, and poorly controlled unstable diabetes (ketoacidosis or an increase in HbA1c of >3% in the 12 weeks before screening), 5) Absolute indications for insulin therapy (Severely infected states, scheduled operation, severe trauma, and so on), 6) history of symptoms of hypoglycemia, 7) poorly controlled hypertension or systolic blood pressure of >160 mmHg or diastolic blood pressure of >100 mmHg, 8) severe retinopathy requiring immediate treatment, 9) during the treatment of malignancy, 10) presence of a severe health problem, not being suitable for the study,11) pregnant or breastfeeding, and 12) inability to participate in the study (including psychiatric and psychosocial problems), as assessed by the investigators.

发起方

TAKAMURA Toshinari